Abstract
Significant research efforts have been concerned over the past few years to design carrier systems that could specifically deliver active agents to the tumor sites, with the purposes of maximizing the therapeutic benefits and minimizing the toxic side-effects. Hyaluronic acid is a type of polysaccharide that has been extensively studied as a selective targeting ligand to cancerous cells that overexpress its specific receptor CD44. The aim of this review is to highlight the role of HA in cancer, focusing on the recent advances of HA-functionalized lipid nanoparticles towards cancer therapy and imaging.
Keywords: Cancer targeting, CD44 receptors, Hyaluronic acid, Lipid nanoparticles, tumor, polysaccharide.
Current Pharmaceutical Design
Title:Hyaluronate-Lipid Nanohybrids: Fruitful Harmony in Cancer Targeting
Volume: 23 Issue: 35
Author(s): May S. Freag*
Affiliation:
- Department of Pharmaceutics, Faculty of Pharmacy, Alexandria University, Alexandria 21521,Egypt
Keywords: Cancer targeting, CD44 receptors, Hyaluronic acid, Lipid nanoparticles, tumor, polysaccharide.
Abstract: Significant research efforts have been concerned over the past few years to design carrier systems that could specifically deliver active agents to the tumor sites, with the purposes of maximizing the therapeutic benefits and minimizing the toxic side-effects. Hyaluronic acid is a type of polysaccharide that has been extensively studied as a selective targeting ligand to cancerous cells that overexpress its specific receptor CD44. The aim of this review is to highlight the role of HA in cancer, focusing on the recent advances of HA-functionalized lipid nanoparticles towards cancer therapy and imaging.
Export Options
About this article
Cite this article as:
Freag S. May*, Hyaluronate-Lipid Nanohybrids: Fruitful Harmony in Cancer Targeting, Current Pharmaceutical Design 2017; 23 (35) . https://dx.doi.org/10.2174/1381612823666170526103015
DOI https://dx.doi.org/10.2174/1381612823666170526103015 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Use of Chronobiotics in the Resynchronization of the Sleep/Wake Cycle. Therapeutical Application in the Early Phases of Alzheimer's Disease
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Oligonucleotide Aptamers for Glioma Targeting: An Update
Central Nervous System Agents in Medicinal Chemistry Biomedical Technologies for In Vitro Screening and Controlled Delivery of Neuroactive Compounds
Central Nervous System Agents in Medicinal Chemistry Targeting the Bone Microenvironment in Metastatic Castration-Resistant Prostate Cancer
Current Drug Targets Ceramide-Based Therapeutics for the Treatment of Cancer
Anti-Cancer Agents in Medicinal Chemistry VEGF-VEGFR System as a Target for Suppressing Inflammation and other Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets New Drugs for Immune Targeting
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Apoptosis in the Dentate Nucleus Following Kindling-induced Seizures in Rats
CNS & Neurological Disorders - Drug Targets Cell Death in Mammalian Development
Current Pharmaceutical Design Therapeutic Targeting of TRPV1 by Resiniferatoxin, from Preclinical Studies to Clinical Trials
Current Topics in Medicinal Chemistry Metabolites of Dietary Protein and Peptides by Intestinal Microbes and their Impacts on Gut
Current Protein & Peptide Science Erythropoietin and mTOR: A “One-Two Punch” for Aging-Related Disorders Accompanied by Enhanced Life Expectancy
Current Neurovascular Research An Effective Brain Imaging Biomarker for AD and aMCI: ALFF in Slow-5 Frequency Band
Current Alzheimer Research Anti-VEGF Compounds in the Treatment of Neovascular Age Related Macular Degeneration
Current Drug Targets Microporation Techniques for Enhanced Delivery of Therapeutic Agents
Recent Patents on Drug Delivery & Formulation Rational Targeting of the Urokinase Receptor (uPAR): Development of Antagonists and Non-Invasive Imaging Probes
Current Drug Targets Trends in the Design and Application of Optical Chemosensors in Pharmaceutical and Biomedical Analysis
Current Pharmaceutical Analysis Pentoxifylline Use in Dermatology
Inflammation & Allergy - Drug Targets (Discontinued) Progresses and Challenges in Optimization of Human Pluripotent Stem Cell Culture
Current Stem Cell Research & Therapy HspB5/αB-Crystallin: Properties and Current Progress in Neuropathy
Current Neurovascular Research